China's CSPC Pharmaceutical Group to partner with AstraZeneca for renal disease drug
02/07/2026 09:55
China's CSPC Pharmaceutical Group to partner with AstraZeneca for renal disease drug July 2 (Reuters) - CSPC Pharmaceutical Group 1093.HK said on Thursday it had entered into an agreement with London-listed AstraZeneca AZN.L to jointly develop pre-clinical candidates with potential to treat renal diseases using the group's siRNA drug discovery platform.
AstraZeneca will have the option to obtain the exclusive rights for the development, manufacturing and commercialisation of the drug globally or outside of China in exchange for payments totalling $1.77 billion, including an upfront payment of $30 million, the group added.
(Reporting by Sherin Sunny in Bengaluru)
Recent news on AstraZeneca
See all newsUK Stocks-Factors to watch on July 10 (updated)
UK Stocks-Factors to watch on July 10
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight (updated)
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight
UK's FTSE 100 ticks lower as AstraZeneca drag offsets banks, mining gains